Kevin Pojasek, Enara Bio CEO
October 3, 2024 04:00 AM EDT
Financing
R&D

Enara Bio’s $32.5M Se­ries B to sup­port lead dark anti­gen pro­gram for GI can­cers

Ayisha Sharma

News Reporter

Enara Bio has snagged $32.5 mil­lion in a Se­ries B fundraise, backed in part by Pfiz­er’s ven­ture arm, to help de­vel­op a pre­clin­i­cal pipeline of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

BioN­Tech opens the hood on its AI am­bi­tions, and they're not just for mR­NA

EMA looks to make its drug ap­proval process­es more ef­fi­cient

Ex­clu­sive: Af­ter dis­cov­er­ing an­tibi­otics with AI, a 31-year-old first-time CEO rais­es $17M to fight ag­ing

Lil­ly in­vests $4.5B in new In­di­ana site to bring clin­i­cal man­u­fac­tur­ing in-house

Scoop: Found­ing CEO leaves Atom­wise, cast­ing doubt over a once high-fly­ing AI start­up 

sponsored

3 Tiers for AAV Po­ten­cy As­say De­vel­op­ment Suc­cess

A service from the Financial Times